1.
Int J Technol Assess Health Care
; 14(3): 514-25, 1998.
Artigo
em Inglês
| MEDLINE
| ID: mdl-9780538
RESUMO
Markov modeling was used to evaluate the cost-effectiveness of octreotide in treating carcinoid syndrome and VIPoma. For each condition, using octreotide was associated with doubled survival time. Octreotide was cost-effective for treating carcinoid tumor ($752 per additional year of life, two additional years on average), and cost saving for VIPoma.